| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.08 | 0.04 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.04 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.082 | 0.04 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.07 | 0.04 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.079 | 0.05 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.05 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.05 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.05 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.05 |